[
  {
    "ts": null,
    "headline": "1 Profitable Stock Worth Investigating and 2 We Turn Down",
    "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
    "url": "https://finnhub.io/api/news?id=c003b406132f9aebbd8c4cf9713ca20e1c9ac406b617c940004092e1678e98e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756214870,
      "headline": "1 Profitable Stock Worth Investigating and 2 We Turn Down",
      "id": 136530289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
      "url": "https://finnhub.io/api/news?id=c003b406132f9aebbd8c4cf9713ca20e1c9ac406b617c940004092e1678e98e2"
    }
  },
  {
    "ts": null,
    "headline": "Scenic Enters License and Research Agreement with Alnylam",
    "summary": "Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. \"Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets",
    "url": "https://finnhub.io/api/news?id=b6a105ace4587b5784413bdd034cb91d77f0a70f29971ebf240c93f25b54dc9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756198800,
      "headline": "Scenic Enters License and Research Agreement with Alnylam",
      "id": 136524066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. \"Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets",
      "url": "https://finnhub.io/api/news?id=b6a105ace4587b5784413bdd034cb91d77f0a70f29971ebf240c93f25b54dc9e"
    }
  }
]